The treatment landscape of CLL has dramatically changed over the last decade with the advent of two classes of therapy: Bruton’s tyrosine kinase (BTK) inhibitor and B-cell leukemia/lymphoma-2 (BCL-2) inhibitors. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.